MedTrace Logo

Controlled Ceasing of Colchicine Therapy in Familial Mediterranean Fever (FMF) Patients With Single MEFV (Mediterranean Fever) Gene Mutation

NCT02175589 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2014-06-26

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effect of discontinuation of colchicine treatment in a specific group of asymptomatic FMF patients with a single mutation in MEFV gene, both from a clinical and laboratory aspects.

Conditions

  • Familial Mediterranean Fever

Interventions

OTHER

Colchicine Cessation

Colchicine Cessation

Sponsors & Collaborators

  • Schneider Children's Hospital

    collaborator OTHER

  • Rambam Health Care Campus

    lead OTHER

Principal Investigators

  • Yonatan Butbul, MD · Rambam Health Care Campus

  • Riva Brik, MD · Rambam Health Care Campus

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
2 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2015-01-31
Completion
2015-01-31

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02175589 on ClinicalTrials.gov